NASDAQ:KRSA Cyclerion Therapeutics Q3 2026 Earnings Results & Report $30.43 -0.13 (-0.43%) Closing price 11/5/2026 04:00 PM EasternExtended Trading$30.36 -0.07 (-0.23%) As of 11/5/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cyclerion Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$3.19 versus the -$50.40 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeBefore Market OpensConference Call7:00 AM ET Cyclerion Therapeutics EPS ResultsActual EPS-$3.19Consensus EPS -$50.40Beat/MissBeat by +$47.21One Year Ago EPSN/ACyclerion Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$550 thousandBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCyclerion Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cyclerion Therapeutics Q3 2026 Earnings FAQ Did Cyclerion Therapeutics beat earnings estimates for Q3 2026? Cyclerion Therapeutics (NASDAQ:KRSA) reported earnings of -$3.19 per share for Q3 2026, beating the consensus estimate of -$50.40. The report was announced on Thursday, November 5, 2026. When is Cyclerion Therapeutics' next earnings date? Cyclerion Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cyclerion Therapeutics on the company's earnings history page. Cyclerion Therapeutics Earnings HeadlinesKorsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 5 at 7:00 AM | globenewswire.comKorsana Biosciences to Participate in Upcoming Investor ConferencesNovember 2, 2026 | globenewswire.comTrump’s Secret Money ExposedIn 1974, a quiet deal between Henry Kissinger and the Saudis reshaped America's monetary order overnight, with no announcement and no vote in Congress. Decades later, the dollar had lost more than 84% of its purchasing power even as millionaire ranks surged into the millions. Financial reporter Kimi Weintraub sits down to explore a new, largely unnoticed shift in America's monetary system, one tied to executive orders and a reported 13-nation agreement. | Porter & Company (Ad)Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Has Average Target Price of $53.00 According to AnalystsOctober 28, 2026 | americanbankingnews.comKorsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 MillionSeptember 8, 2026 | globenewswire.comCyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s PipelineApril 21, 2026 | finance.yahoo.comSee More Cyclerion Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclerion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclerion Therapeutics and other key companies, straight to your email. Email Address About Cyclerion TherapeuticsCyclerion Therapeutics (NASDAQ:KRSA) was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company’s research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling. Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis. These products were investigational and had not been approved for commercial use. The company operated primarily through research and development activities and clinical collaborations rather than through a commercial product business. Cyclerion was previously led by Peter Hecht, who served as chief executive officer. Public information about the company’s current operations and the relationship between Cyclerion Therapeutics and the cited NASDAQ symbol KRSA is limited; the company was historically associated with the ticker CYCN.View Cyclerion Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to WatchQualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a CatchUber's Profit Drop: A Speed Bump or Structural Shift?Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What's Still Missing?Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Datadog's Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
